Please login to the form below

Not currently logged in

Pharma and biotech leaders back ’no deal’ Brexit warning

Ongoing division in Conservative party means 'no deal' remains a possibility

A cross-party committee of MPs has urged the Government to secure a post-Brexit deal with Europe to protect patients and the UK's pharma and biotech sectors.

The BEIS Strategy Committee has published its report ‘The impact of Brexit on the pharmaceutical sector’ today, and called for the government to secure the closest possible regulatory alignment with the European Medicines Agency as well as minimum border friction.

Little in the report will be of surprise to the pharma and biotech sectors, as much of the evidence was drawn from their testimony.  However the report has arrived as Brexit talks reach another crossroads – thanks to a very public disagreement within the government and Conservative party about which Brexit path the country should follow.

The report warns that patients are at risk of harm and the UK pharmaceutical sector could lose its status as a world leading centre for research.

Rachel Reeves

In the course of its inquiries last year, a wide range of life science leaders - including Mike Thompson of pharma association the ABPI -  had informed the committee there were no likely upsides to Brexit for the sector.

The Committee, chaired by Rachel Reeves MP (pictured) reached a very similar conclusion, saying today:"what little benefits there may be from regulatory divergence [from Europe], these would be greatly overshadowed by the costs and loss of markets and influence the UK would face."

The threat of a ‘no deal’ scenario, while unthinkable to many, is still a possibility – thanks largely to  those deep divisions within the Government itself and the Conservative parliamentary party. While Prime Minister Theresa May is committed to leaving the customs union and the single market, her proposals don’t go far enough for some Tories - with foreign secretary Boris Johnson and high profile backbencher Jacob Rees-Mogg both openly criticising her policy.

May wants to propose a customs partnership, which would involve the UK collecting tariffs on behalf of the EU. However the pro-Brexit faction want to see a “max fac” model, which would use technology to monitor borders.

Mike Thompson

A joint statement by the ABPI and the UK BioIndustry Association (BIA) - whose chief executives, Mike Thompson (pictured) and Steve Bates, provided evidence to the Committee - said:

“Every month, 45 million packs of medicine move from the UK to the EU, with 37 million moving the other way.

"Today’s Select Committee Report is right - a Brexit ‘no deal’ would significantly damage public health, patient access to medicines and the UK’s leading pharmaceutical sector. This must be avoided at all costs.

"Securing co-operation on the regulation, trade and supply of medicines must be a priority for both the UK Government and the EU."

Based on evidence given to it, the committee says having to split away from the EMA would impose extra costs of £45,000 ($60,000, €51,000) for each new product released - making the UK an unattractive market for new medicines.

The committee has called for a continued form of membership of the EMA as a priority – however the prime minister’s insistence of leaving the single market and the customs unions is likely to make a deal with Europe on EMA alignment very difficult to achieve.

Rachel Reeves said the Prime Minister had previously set out a positive case for continued co-operation in medicines, but that the ‘clock was now ticking’ on a deal.

“It is now time for the Government to end the uncertainty and translate words into actions. Some form of membership of the EMA is vital to the continued success of the pharma industry and to the welfare of British patients, and the Government should strike a deal to keep some of the organisation’s jobs and facilities in the UK, to continue to share our world-leading expertise.”

Article by
Andrew McConaghie

17th May 2018

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Research Partnership

Research Partnership has joined Ashfield Advisory, the consulting division of healthcare marketing services company, Ashfield. As the market insights specialist...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...